Bone Biologics Corporation (BBLG)
US — Healthcare Sector
Automate Your Wheel Strategy on BBLG
With Tiblio's Option Bot, you can configure your own wheel strategy including BBLG - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BBLG
- Rev/Share 0.0
- Book/Share 0.9145
- PB 0.9624
- Debt/Equity 0.0
- CurrentRatio 12.5899
- ROIC -1.6766
- MktCap 2878843.0
- FreeCF/Share -1.1773
- PFCF -0.7682
- PE -0.3747
- Debt/Assets 0.0
- DivYield 0
- ROE -2.2835
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
About Bone Biologics Corporation (BBLG)
- IPO Date 2021-10-13
- Website https://www.bonebiologics.com
- Industry Medical - Devices
- CEO Mr. Jeffrey Frelick
- Employees 2
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.